You are here:Home-Chemical Inhibitors & Agonists-Others-Other Targets-DHODH inhibitor M62
DHODH inhibitor M62

Chemical Structure : DHODH inhibitor M62

CAS No.: 2757405-32-4

DHODH inhibitor M62

Catalog No.: PC-49788Not For Human Use, Lab Use Only.

DHODH inhibitor M62 is a potent, selective dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 6.9 nM.

Packing Price Stock Quantity
50 mg Get quote
100 mg Get quote
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

    Biological Activity

    DHODH inhibitor M62 is a potent, selective dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 6.9 nM.
    M62 inhibits the proliferation of human CRC cells in vitro with IC50 values ranging from 10.61 to 72.30 nM, HCT116 and HT29 cells are most sensitive (IC50 values of 10.61 and 23.84 nM, respectively).
    M62 shows slightly cytotoxicity against human normal colon endothelial cells (NCM460 and HCoEpiC cells IC50 of 238.77 and 263.60 nM, respectively).
    M62 induces S phase arrest in CRC cells, modulates multiple gene expression changes in CRC cells, significantly upregulates genes DDB2, DDIT3, GADD45A and TP53, downregulates EIF4B, HSP90AB, and RPS6 gene.
    M62 induces the generation of ROS and mitochondrial superoxide, and decreases the production of ΔΨm and ATP, induces DNA damage in CRC cells.
    M62 inhibits the expression of DNA repair proteins (ATM, RAD51, BRCA1, and 53BP1) and inhibits the PI3K/AKT/mTOR signaling pathway in CRC cells.
    M62 (40 mg/kg, once daily oral gavage) inhibits subcutaneous CRC tumor growth in HCT116 xenograft models.

    Physicochemical Properties

    M.Wt 503.81
    Formula C21H15ClF5N3O4
    Appearance Solid
    CAS No.
    Storage
    Solide Powder
    -20°C 12 Months; 4°C 6 Months
    In Solvent
    -80°C 6 Months; -20°C 6 Months
    Shipping
    Solubility

    10 mM in DMSO

    Chemical Name/SMILES

    (S,Z)-N-(2-chloro-6-fluorophenyl)-4-(2-cyano-3-hydroxybut-2-enamido)-5-fluoro-2-((1,1,1-trifluoropropan-2-yl)oxy)benzamide

    References

    1. Li C, et al. Design, synthesis, and biological evaluation of a novel series of teriflunomide derivatives as potent human dihydroorotate dehydrogenase inhibitors for malignancy treatment. J Med Chem. 2021;64(24):18175-18192.

    2. Xiaowei Yang, et al. A novel and potent dihydroorotate dehydrogenase inhibitor suppresses the proliferation of colorectal cancer by inducing mitochondrial dysfunction and DNA damage. https://doi.org/10.1002/mog2.6

    Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

    Contact Us sales@probechem.com

    Bulk Inquiry

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • *Additional Information:

    Get Quote

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • Additional Information: